3 completed, 2 terminated, 1 unknown, 1 withdrawn. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Ambisome: new trials by email Literature Review of Ambisome trials Research Report on Ambisome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short Course Regimens for Treatment of PKDL (Sudan) Paromomycin, Ambisome, Miltefosine - PKDL - Post-Kala-Azar Dermal Leishmanioid | Phase 2 | Unknown | Drugs for Neglected Diseases | 110 | 2018-05-09 | 2020-01-18 |
| High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Fluconazole, Amphotericin B - Cryptococcal Meningitis, HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 168 | 2010-04-16 | 2021-11-04 |
| Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Liposomal amphotericin B (Ambisome) - Visceral Leishmaniasis | Phase 2 | Terminated | Drugs for Neglected Diseases | 124 | 2009-04-01 | 2016-01-21 |
| Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections Voriconazole, Liposomal amphotericin B - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 120 | 2006-11-01 | 2012-08-07 |
| PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation AmBisome - Fungus Diseases | Phase 2 | Completed | Gilead Sciences | 34 | 2006-06-01 | 2010-02-12 |
| Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis Micafungin, Liposomal Amphotericin B - Aspergillosis | Phase 2 | Terminated | Astellas Pharma Inc | 2 | 2002-12-01 | 2014-08-20 |
| SCH708980 With and Without AmBisome for Visceral Leishmaniasis SCH708980 Anti-IL-10 monoclonal, AmBisome - Leishmaniasis, Effects of Immunotherapy | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-08-28 |
Aspergillosis (1) · HIV Infections (1) · Leishmaniasis (1) · Leishmaniasis, Visceral (1) · Leukemia, Myeloid, Acute (1) · Meningitis (1) · Meningitis, Cryptococcal (1) · Mycoses (1) · Myelodysplastic Syndromes (1)
Drugs for Neglected Diseases (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Astellas Pharma Inc (1) · Gilead Sciences (1) · M.D. Anderson Cancer Center (1)
United States (3) · India (2) · Sudan (2) · Ethiopia (1) · Italy (1) · Kenya (1) · Peru (1) · South Africa (1) · Thailand (1) · Uganda (1) · Zimbabwe (1)
David Sacks, PhD (1) · Gloria N Mattiuzzi, MD (1) · Luigi Picaro, MD (1) · Robert A. Larsen, MD (1) · Shyam Sundar, MD (1) · Sisay Yifru, MD (1) · Umesh G. Lalloo, MD, FRCP (1)
PMID 21375777, PMID 24454970, PMID 36780493, PMID 37988402, PMID 39007942